Worthington M, Irvine L M, Crook D, Lees B, Shaw R W, Stevenson J C
Wynn Institute for Metabolic Research, London, United Kingdom.
Fertil Steril. 1993 Mar;59(3):522-6. doi: 10.1016/s0015-0282(16)55793-8.
To study some of the metabolic effects of oral gestrinone on plasma lipoprotein risk markers for cardiovascular disease and on bone density, a risk marker for osteoporosis.
Randomized double-blind study.
All patients were referred to Gynaecology Clinic of Royal Free Hospital Medical School.
Twenty premenopausal women with laparoscopically confirmed endometriosis.
Subjects were randomized in a double-blind fashion to receive either 1.25 mg or 2.5 mg gestrinone two times per week for 6 months.
Laparoscopy was performed before treatment, and clinical responses were determined by second laparoscopy after 6 months. Plasma lipid and bone density measurements during and after therapy were compared with baseline.
Median total endometriosis scores decreased from 7.5 to 1.0 in the 1.25-mg group and from 7.0 to 0 in the 2.5-mg group. There were no significant between-group differences in endometriosis scores. At both doses, bone density in the spine and the proximal femur was conserved, but plasma concentrations of low-density lipoproteins rose by 13% and those of high-density lipoproteins fell by 40%.
Reducing the dose of gestrinone to 1.25 mg appeared to maintain the therapeutic effectiveness of this treatment but was still associated with potentially unfavorable effects on lipids and lipoproteins.
研究口服孕三烯酮对心血管疾病的血浆脂蛋白风险标志物以及对骨质疏松症风险标志物骨密度的一些代谢影响。
随机双盲研究。
所有患者均被转诊至皇家自由医院医学院妇科诊所。
20名经腹腔镜确诊为子宫内膜异位症的绝经前女性。
受试者以双盲方式随机分组，每周两次接受1.25毫克或2.5毫克孕三烯酮治疗，为期6个月。
治疗前进行腹腔镜检查，6个月后通过第二次腹腔镜检查确定临床反应。将治疗期间及治疗后的血浆脂质和骨密度测量结果与基线进行比较。
1.25毫克组的子宫内膜异位症总评分中位数从7.5降至1.0，2.5毫克组从7.0降至0。两组间子宫内膜异位症评分无显著差异。在两个剂量下，脊柱和股骨近端的骨密度得以维持，但低密度脂蛋白的血浆浓度升高了13%，高密度脂蛋白的血浆浓度下降了40%。
将孕三烯酮剂量降至1.25毫克似乎可维持该治疗的有效性，但仍与对脂质和脂蛋白的潜在不利影响相关。
